The purpose of the study is to compare how long patients stay free of disease progression when venetoclax is continued for a longer period versus stopping after the initial six‑month course. After the six cycles of the combination, participants are randomly assigned—by chance—to either keep taking venetoclax for up to about 20 cycles or to stop the drug. All participants are then monitored with regular doctor visits, blood tests, and scans to check for any return of disease or side effects. The main outcome measured is progression free survival, which counts the time from random assignment until the disease gets worse or the patient dies.

The purpose is to find a safe dose of the three‑drug regimen and to see how well it can clear the cancer cells, especially in patients with certain genetic changes such as TP53 or IGHV. Participants will receive the medicines on a planned schedule over several months, with regular check‑ups that may include blood tests and a test called flow cytometry to measure tiny amounts of remaining cancer cells. Safety will be monitored by recording any side effects, and success will be judged by how many patients achieve “MRD negativity,” meaning very few cancer cells can be detected.

During the study, participants will take these medications as part of a treatment plan. The process involves monitoring the disease to see how the body responds to the combined medicines. The study will follow the participants over time to see how long the treatment keeps the cancer under control and to ensure the medications are being used safely.

The purpose of this research is to determine how well NX-5948 works in treating adults with CLL or SLL that has come back or not responded to previous treatments. During the study, participants will receive NX-5948 capsules daily. The maximum daily dose that may be given is 600 milligrams, and treatment may continue for up to 28 days per treatment cycle.

Throughout the study, doctors will monitor participants’ health through regular check-ups and various medical tests. They will look at how the cancer responds to the treatment and keep track of any side effects that may occur. The study will collect information about how long the treatment effects last and how it affects participants’ overall health.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

The purpose of this study is to evaluate how effective and safe this combination treatment is for patients whose CLL has returned after previous treatment. Participants in the study will receive Venetoclax in the form of a film-coated tablet taken orally, and Obinutuzumab as a solution for infusion, which means it is given directly into a vein. The study will follow participants over a period of time to monitor changes in their disease and any side effects they may experience.

Throughout the study, participants will be assessed to see how their disease responds to the treatment. The study aims to understand the overall response rate, which is the proportion of participants who show improvement in their condition. Other aspects being evaluated include how long it takes for the treatment to start working, how long the response lasts, and the time until any further treatment is needed. The study will also look at progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time a patient lives after starting the treatment.

The purpose of this study is to evaluate the long-term safety of these therapies. Patients who have received these treatments will be monitored over time to check for any late-onset side effects or serious health events. This includes looking for any new or returning cancers, serious infections, or other significant health issues. The study will also track the presence of certain cells in the blood, such as B and T lymphocytes, and other health indicators like height and weight in children. The presence of any remaining modified cells from the therapy will also be checked.

Participants in this study will have regular follow-up visits where their health will be assessed. This includes checking for any signs of the cancer returning or progressing and monitoring overall survival rates. The study aims to ensure that the treatments are safe in the long term and to gather important information that can help improve future therapies. The study is expected to continue until the end of 2040, providing valuable insights into the long-term effects of these innovative treatments.